Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
Cart
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Home
Journals
Radiology and Oncology
Volume 48 (2014): Issue 4 (December 2014)
Open Access
Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
Matjaz Zwitter
Matjaz Zwitter
,
Karmen Stanic
Karmen Stanic
,
Mirjana Rajer
Mirjana Rajer
,
Izidor Kern
Izidor Kern
,
Martina Vrankar
Martina Vrankar
,
Natalija Edelbaher
Natalija Edelbaher
and
Viljem Kovac
Viljem Kovac
| Nov 05, 2014
Radiology and Oncology
Volume 48 (2014): Issue 4 (December 2014)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Nov 05, 2014
Page range:
361 - 368
Received:
Aug 25, 2014
Accepted:
Sep 08, 2014
DOI:
https://doi.org/10.2478/raon-2014-0038
Keywords
Non-small cell lung cancer
,
EGFR activating mutations
,
gemcitabine
,
cisplatin
,
erlotinib
,
intercalated therapy
,
metabolic response
© by Matjaz Zwitter
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Matjaz Zwitter
Institute of Oncology Ljubljana, Ljubljana, Slovenia / Faculty of Medicine, University of Maribor, Maribor, Slovenia
Karmen Stanic
Institute of Oncology Ljubljana, Ljubljana, Slovenia
Mirjana Rajer
Institute of Oncology Ljubljana, Ljubljana
Izidor Kern
University Hospital for Pulmonary Diseases Golnik, Golnik, Slovenia
Martina Vrankar
Institute of Oncology Ljubljana, Ljubljana, Slovenia
Natalija Edelbaher
Department of Pulmonary Medicine, University Clinical Centre Maribor, Maribor, Slovenia
Viljem Kovac
Institute of Oncology Ljubljana, Ljubljana, Slovenia